ETRA · Electra Therapeutics
Electra Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company develops therapies that targets signal regulatory proteins for the treatment of novel targets for treatment of immune-mediated diseases and cancer. Its lead product candidate is ipsoprubart, that targets signal regulatory protein on the cell surface of myeloid and T cells and depletes pathological immune cells, treatment for secondary hemophagocytic lymphohistiocytosis and T/NK Cell Malignancies; ELA822, a novel SIRP-specific monoclonal antibody for deplete activated T cells, treatment for T cell mediated immune disorders. Electra Therapeutics, Inc. was incorporated in 2018 and is based in South San Francisco, California.
Market Cap
509.8M
52 Wk Range
$6.87 - $15.50
Previous Close
$8.94
Open
$8.85
Volume
376,123
Day Range
$8.07 - $9.65
Enterprise Value
161.2M
Cash
402.5M
Avg Qtr Burn
-18.91M
Insider Ownership
5.29%
Institutional Own.
94.20%
Qtr Updated
Sep 30th 2026
